Oncotarget

Research Perspectives:

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link

Simone Fulda _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2011; 2:418-421. https://doi.org/10.18632/oncotarget.277

Metrics: PDF 2120 views  |   HTML 3001 views  |   ?  


Abstract

Simone Fulda

1Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528 Frankfurt, Germany

Keywords: cancer, apoptosis, chemotherapy, proteasome inhibitor, TRAIL

Received: April 19, 2011; Accepted: May 14, 2011; Published: May 16, 2011;

Correspondence:

Simone Fulda, e-mail:

Abstract

The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. However, the identification of the underlying molecular mechanisms of this synergistic cell death induction has been ongoing over the last years. A recent study identifies a new mechanism of action for the synergism of TRAIL and Bortezomib.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 277